300 million yuan transfer of four pharmaceutical companies no one asked whether the listed pharmaceutical companies to sell assets into the wind behind the logic is?

On September 9th, the shares of four subsidiaries of Laimei Pharmaceuticals were again listed on the Chongqing Stock Exchange for transfer.
this is the 8th transfer of the four subsidiaries by Lemex Pharmaceuticals, the previous seven transfers have not been successful.
's transferred underlying shares are 100% of Hunan Kangyuan Pharmaceutical Co., Ltd., with a transfer base price of 200 million yuan, Sichuan Yanzheng Pharmaceutical Co., Ltd. with a 100% stake and a transfer base price of 110 million yuan, Chongqing Laimei Health Industry Co., Ltd. with a 60% stake with a transfer base price of 0.0001 million yuan, and Chongqing Laiyuan Chinese Medicine tablet Co., Ltd. with a transfer base price of 12.55 million yuan.
2020 results released by La remei Pharmaceuticals showed operating income of 598 million yuan in the first half of this year, down 24.0 percent year-on-year, while net profit attributable to the stock was 8.1 million yuan, down 115 percent year-on-year.
of the four subsidiaries listed for transfer, Sichuan Yuzheng's net profit was 2.63 million yuan, Hunan Kangyuan's loss was 17.41 million yuan, Lemei Health's net profit was 1.48 million yuan, and Lai's loss was 1.94 million yuan.
Pharmaceuticals said the continued public disposal of the underlying stake is the company's need to accelerate its focus on the development of the main industry and avoid competition with controlling shareholders.
01 performance pressure surge Pharmaceutical companies sell assets to slimming down pharmaceutical companies "slimming down" is not an example.
affected by the epidemic and policies, drug companies will generally decline in 2020.
MNC, including Johnson and Johnson, Pfizer and Bayer, all fell in varying degrees.
seems to be in a more difficult position than multinational pharmaceutical companies.
more than half of pharmaceutical companies reported negative revenue or profit growth, according to the company's revenue figures, which have been disclosed for the 2020 half year.
, pharmaceutical companies have started to "sell and sell", through the sale of assets, equity and even technology and product transfer, in order to focus on the main industry, in-house capital, seeking development is not difficult to understand.
According to incomplete statistics, Tai'anTang, Dong'a gum, Northeast Pharmaceuticals, Kangmei Pharmaceuticals, Beida Pharmaceuticals, People's Fu Pharmaceuticals, Tianshili and many other well-known pharmaceutical companies are selling assets or "slimming down" in different forms to speed up the flow of funds and improve the efficiency of asset use.
August 27, Kangmei Pharmaceuticals announced that the company achieved revenue of 2.517 billion yuan, down 69.05 percent year-on-year, and a net loss of 1.424 billion yuan, compared with a profit of 85.5 million yuan a year earlier.
, Kangmei Pharmaceuticals said that the reporting period the company focused on the main industry, adjust business strategy, affected by the outbreak, revenue decreased year-on-year. The contents of the
announcement also indicate that its wholly-owned subsidiary Kangmei Health Industry Investment Co., Ltd. intends to sell two state-owned construction land use rights and their above- and underground buildings and/or construction projects located in the AH040248 block of Zhangzhou A District, Haizhu District, Guangzhou, and the cross-municipal road link (10)-2 of the Internet Innovation Cluster in Haizhu District, Guangzhou City, for not more than 113 million yuan.
Pharmaceuticals said the move was to further incuss assets and focus on the main business.
because of the performance loss seriously choose to sell the industry is also Dong A gum.
August 26, Dong'a Gum released its semi-annual report showing that the company's first-half operating income was RMB1,095 million, down 42.06 percent from RMB1.89 billion a year earlier, while the net profit attributable to shareholders of listed companies was RMB84.02 million, down 143.54 percent from a year earlier.
the same day that the results were announced, Dong A gum began a "slimming" program, announcing the transfer of its 25% stake in China Resources Onde Biopharmaceutical Co., Ltd. to China Resources Biopharmaceuticals.
the related transaction has little impact on the company's overall earnings, and is able to recover equity investment funds of RMB74,408.425 million, increasing the company's cash flow.
fu medicine is also for performance to slim down the representative.
August 21, the company reported half-yearly operating income of 9,656 million yuan in the first half of 2020, down 8.23% from a year earlier, and net profit attributable to shareholders of listed companies was 392 million yuan, up 16.56% from a year earlier.
August 5, the company signed a contract with Chongqing Pharmaceuticals to transfer a 70% stake in Sichuan People's Fu Pharmaceuticals to Chongqing Pharmaceuticals for 362 million yuan.
the company had previously sold its man, Fu Zhongxiang Medical Management Co., Ltd., for $967 million.
according to People's Fu Pharmaceuticals, this move on the one hand, the divestiture of non-core pharmaceutical assets, continue to optimize the business, capital structure, on the other hand, adhere to the focus of resources to develop established professional sub-areas to achieve business focus.
Haizheng Pharmaceuticals is also selling assets through the industry.
incomplete statistics, from the beginning of 2019 to the beginning of 2010, Haizheng Pharmaceuticals returned 3,771 million yuan through the sale of assets.
August 18, Haizheng Pharmaceuticals released its semi-annual report showing that operating income in the first half of the year was 5.31 billion yuan, and net profit attributable to shareholders of listed companies reached 240 million yuan, up 357.31 percent year-on-year.
of active assets and focusing on core business has become the choice of more and more pharmaceutical companies.
August 21st, Beda Pharmaceuticals announced that it would sell a 100% stake in Zhejiang Bayda Pharmaceuticals Technology Co., Ltd. for about 251 million yuan in order to accelerate the withdrawal of funds, replenish cash flow and help new drug research and development.
August 28, Yan'an Bikang announced its proposed transfer of its Jia'an Information Center project under construction at a proposed asset transfer price of 252 million yuan, and the transfer of the land use rights of Xinyi Smart Health Town and its seat at a transfer price of not less than RMB1.5 billion.
Yan'an Bikang said the aim was to improve the efficiency of the company's asset use and optimize the company's asset structure.
Faced with the outbreak of black swans, pharmaceutical companies may have encountered cash flow difficulties, pharmaceutical companies are gradually moving from expansion-style "buy and buy" to naturalized "sell and sell" in order to seek further development.
02 Transfer of Products and Technologies Focus on core business In addition to the sale of equity or assets for the purpose of focusing on the core business, improving asset efficiency and optimizing the company's asset structure, there are not a few direct transfers of technology or product approvals and optimization of the enterprise product structure.
industry insiders revealed that, with the State Health Insurance Administration previously clear Chinese medicine drink tablets, Chinese medicine formula particles, chinese medicine exclusive varieties are not included in the collection, the current transfer of Chinese traditional medicine approval has become a new wind.
June 15, Fangsheng Pharmaceuticals announced that its controlling subsidiary Xiangya Pharmaceuticals commissioned the Hunan Provincial Stock Exchange to organize the transfer of "gastric healing particles" drug production technology.
, FangSheng Pharmaceuticals said it was unable to confirm the specific amount of research and development investment because the batch was obtained earlier.
2017-2019, sales of gastric particles were RMB1.942 million, RMB3.1162 million and RMB1.8807 million, respectively, accounting for 2.29%, 3.07% and 2.03% of Fangsheng Pharmaceutical's current revenue.
Fangsheng Pharmaceuticals said that the transfer of the product will optimize the company's product structure, but also to promote the company and subsidiaries to better implement the "concentration of core resources to build large products" marketing strategy, focus on doing a good job of gastric choice capsule type market development, conducive to its long-term development.
with the MAH system to unlock drug approval transactions, pharmaceutical companies in accordance with their own conditions for product transfer, restructuring or change their product marketing model.
July 3, KYU Pharmaceuticals announced its changes to clinical trial bidders and patent transfer announcement, the announcement shows that KYU Pharmaceuticals to Sun Ascending (Zhangzhou) transfer of left hydroxyphenol capsule technology and related intellectual property rights, LSP capsule is the new cough phlegm compound preparation, intended to be used to treat acute and chronic upper respiratory tract infection caused by cough, cough sputum.
said the move is conducive to the company's rational distribution of advantageous resources, focusing on the research and development and sales of key products, in line with the company's long-term development interests.
In a unique way, on July 24th Shuangcheng Pharmaceuticals proposed to grant Hainan Zhong and Pharmaceutical Co., Ltd. the right to own specific intellectual property rights and production technologies related to ideba peptide injections in designated areas for RMB28 million.
understood that Shuangcheng Pharmaceuticals has specific intellectual property rights related to edide injections, and in January 2019 submitted a drug market license registration application.
, pharmaceutical companies are moving towards a high concentration, whether it's the sale of equity assets or the transfer of product technology.
through the sale of non-core assets to "slim down", focus on a strong business, help pharmaceutical companies to further in-live assets, optimize resource allocation, focus on core business, control operational risks, improve management efficiency.
With the deepening of medical reform, consistent evaluation, volume procurement and other policies, listed pharmaceutical companies to open the nuclear action, the extension of extensive expansion of mergers and acquisitions development, focusing on strong profitability, development potential of the main industry, has become more and more pharmaceutical companies in the process of strategic transformation of the inevitable choice.